Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Ropert

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Plos One|February 23, 2011
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenibRomain Coriat, Hervé Gouya, Olivier Mir, et al.
The American Journal of Pathology|March 17, 2011
Netrin-4 delays colorectal cancer carcinomatosis by inhibiting tumor angiogenesisClarisse Eveno, Dong Broqueres-You, Jean-Guillaume Feron, et al.
Anti-Cancer Drugs|June 16, 2012
Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2Olivier Mir, Romain Coriat, Marion Dhooge, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 9, 2011
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasmaLionel Faivre, Charline Gomo, Olivier Mir, et al.
Medical Oncology (Northwood, London, England)|March 20, 2012
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenibOlivier Mir, Romain Coriat, Pascaline Boudou-Rouquette, et al.
Plos One|June 6, 2012
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinomaOlivier Mir, Romain Coriat, Benoit Blanchet, et al.
Investigational New Drugs|October 19, 2011
Saturable absorption of sorafenib in patients with solid tumors: a population modelMarilyne Hornecker, Benoit Blanchet, Bertrand Billemont, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2012
Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancerOlivier Mir, Pascaline Boudou-Rouquette, Julie Giroux, et al.
Expert Review of Anticancer Therapy|July 24, 2013
Current, new and novel therapy for castration-resistant prostate cancerJosep M Gaya, Youness Ahallal, Rafael Sanchez-Salas, et al.
Pharmaceutical Research|June 22, 2011
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patientsMichel Tod, Olivier Mir, Natacha Bancelin, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Plos One|February 23, 2011
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenibRomain Coriat, Hervé Gouya, Olivier Mir, et al.
The American Journal of Pathology|March 17, 2011
Netrin-4 delays colorectal cancer carcinomatosis by inhibiting tumor angiogenesisClarisse Eveno, Dong Broqueres-You, Jean-Guillaume Feron, et al.
Anti-Cancer Drugs|June 16, 2012
Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2Olivier Mir, Romain Coriat, Marion Dhooge, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 9, 2011
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasmaLionel Faivre, Charline Gomo, Olivier Mir, et al.
Medical Oncology (Northwood, London, England)|March 20, 2012
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenibOlivier Mir, Romain Coriat, Pascaline Boudou-Rouquette, et al.
Plos One|June 6, 2012
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinomaOlivier Mir, Romain Coriat, Benoit Blanchet, et al.
Investigational New Drugs|October 19, 2011
Saturable absorption of sorafenib in patients with solid tumors: a population modelMarilyne Hornecker, Benoit Blanchet, Bertrand Billemont, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2012
Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancerOlivier Mir, Pascaline Boudou-Rouquette, Julie Giroux, et al.
Expert Review of Anticancer Therapy|July 24, 2013
Current, new and novel therapy for castration-resistant prostate cancerJosep M Gaya, Youness Ahallal, Rafael Sanchez-Salas, et al.
Pharmaceutical Research|June 22, 2011
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patientsMichel Tod, Olivier Mir, Natacha Bancelin, et al.
Pageof 6